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Abstract 
Purpose: To determine the conformation as well as imine double bond configuration of the anti-
Candida oximino ester, 3-(1H-imidazol-1-yl)-1-phenyl- propan-1-one O-3-chlorobenzoyl oxime. 
Methods: The titled compound was synthesized in a four-step reaction sequence using acetophenone 
as a starting material. Spectral analysis, viz, nuclear magnetic resonance (1H NMR and 13C NMR 
spectroscopy) and mass spectrometry (MS) confirmed the chemical structure of the synthesized 
compounds. Subsequently, single crystals of the titled compound were subjected to x-ray 
crystallographic analysis.  
Results: The single crystal x-ray crystallography of the investigated anti-Candida agent revealed its 
conformation and the (E)-configuration of its imine double bond. The titled compound crystallizes in the 
monoclinic space group P21/c with a = 11.1894 (2)Å, b = 19.5577 (4)Å, c = 8.2201 (2)Å, β = 104.919 
(2)º, V = 1738.24 (6)Å3, Z = 4. The molecules are packed in crystal structure by weak non-classical 
intermolecular hydrogen C2—H2A•••O2 interactions. 
Conclusion: X-ray crystallography analysis confirms the (E)-configuration of the titled compound.   
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The increased incidence of fungal infections in 
the last half-century has raised this class of 
infections one of the most current common 
distress. Invasive nosocomial and systemic 
fungal infections tare among the main causes of 
morbidity and mortality, especially in patients 
with compromised immune systems such as 
cancer or AIDS, steroid treatments and in organ 
transplant cases [1-3]. Candida species appear 
to be the main causative agent for nosocomial 
fungal infections with Candida albicans being the 
cause of the majority of invasive candidiases with 
about 30 – 40 % of mortality [4]. 
 
Azole antifungal agents bearing either imidazole 
or 1, 2, 4-triazole moieties constitute the major 
group of the currently available anti-Candida 
agents [5,6]. The titled compound 4 is an azole-
containing anti-Candida agent having the 
imidazole pharmacophore moiety. 
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There is no previous research pertaining to 
explore the configuration of the anti-Candida 
oxime ester 4. Therefore, x-ray crystallography, 
as a doubtless analytical tool, was used to 
determine the configuration of the imine double 







Melting points were determined on a Gallenkamp 
melting point apparatus and were uncorrected. 
NMR spectra were obtained from a Bruker NMR 
spectrometer operating at 500 MHz for 1H and 
125.76 MHz for 13C at the Research Center, 
College of Pharmacy, King Saud University, 
Saudi Arabia. TMS was used as internal 
standard and chemical shift values were 
recorded in ppm on δ scale. The 1H-NMR data 
were represented as follows: chemical shifts, 
multiplicity (s. singlet, d. doublet, t. triplet, m. 
multiplet) and number of protons. The 13C-NMR 
data were represented as chemical shifts and 
type of carbon. Mass spectra were measured on 
Agilent Triple Quadrupole 6410 QQQ LC/MS with 
an electrospray ionization (ESI) source. The X-
ray diffraction measurements of compound 4 
were performed using Bruker SMART APEXII 
CCD diffractometer. Crystallographic data of 
compound 4 has been deposited with the 
Cambridge Crystallographic Data Center 
(supplementary publication number CCDC-
1050446). Copies of the data may be obtained 
free of charge from the Director, CCDC, 12 




phenylpropan-1-one (2)  
 
A mixture containing acetophenone (2.4 g, 20 
mmol), paraformaldehyde (0.81 g, 9 mmol), 
dimethylamine hydrochloride (2.2 g, 27 mmol) 
and catalytic amount of concentrated 
hydrochloric acid (0.1 mL) was heated to reflux 
for two hours in absolute ethanol (5 mL). The 
reaction mixture was cooled to ambient 
temperature and acetone (20 mL) was added to 
precipitate the Mannich base hydrochloride 1. 
Imidazole (2.4 g, 34.8 mmol) was added to a 
solution of compound 1 (3.7 g, 17.4 mmol) in 
water (10 mL) and the reaction mixture was 
heated at reflux temperature for five hours. The 
reaction mixture was cooled and the precipitated 
solid was filtered off to furnish compound 2 (2.7 
g, 77%) mp 368-370 K [7] which was used in the 
next step without any further purification. 
Preparation of (1E)-N-hydroxy-3-(1H-imidazol-
1-yl)-1-phenylpropan-1-imine (3)  
 
The ketone 2 (2.00 g, 10 mmol), hydroxylamine 
hydrochloride (1.39 g, 20 mmol), and KOH (1.12 
g, 20 mmol) in ethanol (10 mL) were refluxed 
under stirring for 18 h. The reaction mixture was 
cooled to room temperature and the insoluble 
materials were filtered off. The filtrate was 
concentrated under vacuum and the residue was 
poured onto ice-cold water (15 mL). The 
precipitated solid was filtered, dried, and 
recrystallized from ethanol to give 1.51 g (70 %) 
of the oxime 3 as colourless crystals mp 428 - 
430 K [8]. 
 
Preparation of (E)-3-(1H-imidazol-1-yl)-1-
phenylpropan-1-one O-3-chloro- benzoyl 
oxime (4)  
 
A solution of the 3-chlorobenzoic acid (1.1 g, 7 
mmol), 1-ethyl-3-(3-dimethylaminopropyl)- 
carbodiimide (EDCI.HCl, 1.40 g, 7.3 mmol) and 
4-dimethylaminopyridine (DMAP, 400 mg) in 
dichloromethane (75 mL) was stirred at ambient 
temperature. The oxime 3 (1.49 g, 6.9 mmol) 
was added and the reaction mixture was further 
stirred for 18 h at ambient temperature. The 
reaction mixture was washed successively with 
water (2 x 20 mL), 10 % NaHCO3 solution (2 x 15 
mL), and water (2 x 15 mL). The organic layer 
was separated, dried (Na2SO4), evaporated 
under reduced pressure and the residue was re-
crystallized (isopropanol) to give 1.51 g (61 %) of 
4 as colourless crystals melting point of 383-385 
K [8].  
 
Evaluation of anti-Candida activity 
 
The MIC values of fluconazole and/or compound 
4 were determined with a microdilution test (M27-
A2 Protocol), according to the reference method 
of the CLSI [9]. Aliquots of the previously 
prepared Candida inocula (100 μL) were added 
to each well of the 96-well microdilution plates; 
each well contained 100 µL of twofold serial 
dilutions of fluconazole or compound 4 (1 μg/mL 
to 500 μg/mL) in RPMI 1640 medium. The plates 
were incubated at 35 °C for 48 h and the 
observed turbidity of each well was measured at 
490 nm with a microplate ELISA reader. The 
MICs for fluconazole and/or compound 4 were 
determined with 80 % growth inhibition at the end 
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The target compound 4 was synthesized as 
depicted in Scheme 1. The ketone 2 was 
obtained from acetophenone via Mannich 
reaction and subsequent substitution of the 
produced Mannich base hydrochloride 1 with 
imidazole to give the pivotal ketone 2. Compound 
2 was allowed to react with hydroxylamine 
hydrochloride in the presence of potassium 
hydroxide to give the oxime 3. Esterification of 
the hydroxyl functionality of compound 3 with 3-
chlorobenzoic acid was successfully achieved 





1H-NMR (CDCl3): δ 3.44 (t, J = 6.5 Hz, 2H, -CH2-
CH2-N), 4.43 (t, J = 6.5 Hz, 2H, -CH2-CH2-N), 
6.98 (s, 1H, -N-CH=CH-N=), 7.03 (s, 1H, -N-
CH=CH-N=), 7.45–7.49 (m, 2H, Ar-H), 7.56-7.61 
(m, 2H, Ar-H, -N-CH=N-), 7.92 (d, J = 7.5 Hz, 2H, 
Ar-H); 13C-NMR (CDCl3): δ 39.9 (-CH2-CH2-N), 
41.5 (-CH2-CH2-N), 119.1 (-N-CH=CH-N=), 
127.9, 128.8, 129.6 (-N-CH=CH-N=, Ar-CH), 






1H-NMR (CDCl3): δ 3.31 (t, J = 7.1 Hz, 2H, -CH2-
CH2-N), 4.28 (t, J = 7.1 Hz, 2H, -CH2-CH2-N), 
6.96 (s, 1H, -N-CH=CH-N=), 7.07 (s, 1H, -N-
CH=CH-N=), 7.29–7.49 (m, 5H, Ar-H), 7.58 (s, 
1H, -N-CH=N-); 13C-NMR (CDCl3): δ 28.3 (-CH2-
CH2-N), 41.8 (-CH2-CH2-N), 119.1 (-N-CH=CH-
N=), 126.1, 128.8, 128.9 (-N-CH=CH-N=, Ar-
CH), 135.1, 137.0 (Ar-C), 139.5 (-N-CH=N-), 
155.4 (C=N-OH); MS m/z (ESI): 216.0 [M + 1]+. 
 
(E)-3-(1H-Imidazol-1-yl)-1-phenylpropan-1-one 
O-3-chlorobenzoyl oxime (4) 
 
1H-NMR (DMSO-d6): δ (ppm) = 3.52 (br. s, 2H, -
CH2-CH2-N), 4.30 (br. s, 2H, -CH2-CH2-N), 6.80 
(s, 1H, -N-CH=CH-N=), 7.17 (s, 1H, -N-CH=CH-
N=), 7.51–7.82 (m, 8H, -N-CH=N-, Ar-H), 8.00 (d, 
J = 1.5 Hz, 2H, Ar-H.); 13C-NMR (DMSO-d6): δ 
30.1 (-CH2-CH2-N), 43.0 (-CH2-CH2-N), 119.3 (-
N-CH=CH-N=), 127.3, 128.1, 128.5, 128.9, 
130.3, 130.9, 131.1, 132.9, 133.6, 133.7 (-N-
CH=CH-N=, Ar-CH, Ar-C), 137.1 (-N-CH=N-), 
161.7 (C=N), 164.8 (C=O); MS m/z (ESI): 354.1 
[M]+. 
 
Crystal structure of the titled compound 4 
 
A single crystal of dimensions, 0.58 mm X 0.39 
mm X 0.21 mm, was selected for x-ray diffraction 
analysis. Data were collected on a Bruker APEX-
II CCD area diffractometer equipped with 
graphite monochromatic CuK\a radiation (λ = 
1.54178 Å) at 296 (2) K. Cell refinement and data 
reduction were done by Bruker SAINT [10]. 
SHELXS-97 [11] was used to solve and refine 
the titled structure. The final refinement was 
conducted by full- matrix least-squares 
techniques with anisotropic thermal data for non-
hydrogen atoms on F2 [12]. All the hydrogen 
atoms were placed in calculated positions and 
constrained to ride on their parent atoms [12]. 
Multi-scan absorption correction was applied by 
the use of SADABS software [10]. The 
crystallographic data and refinement information 
are listed in Table 1. The selected bond lengths 


























Scheme 1: Synthesis of the target compound 4. Reagents and conditions: i) HN(CH3)2.HCl, (CH2O)n, conc. HCl, 
ethanol, reflux, 2 h; ii) Imidazole, water, reflux, 5 h; iii) H2NOH.HCl, KOH, ethanol, reflux, 18 h; iv) 3-
Chlorobenzoic acid, EDCI.HCl, DMAP, DCM, rt, 18 h 
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The labelled displacement ellipsoid plot of this 
molecule is shown in Figure 1 in which minor 
disordered component has been omitted for 
clarity. Figure 2 depicts the packing of the 
molecules in the crystal structure. 
 
 
Table 1: Crystallographic data and refinement information 
 
Molecular formula C19H16ClN3O2 
Mr 353.80 
Crystal system, space group Monoclinic, P21/c 
Temperature (K) 296(2) 
a, b, c (Å) 11.1894 (2), 19.5577 (4), 8.2201 (2) 
β (°) 104.919 (2) 
V (Å3) 1738.24 (6) 
Z 4 
Radiation type Cu Kα 
µ (mm−1) 2.09 
Crystal size (mm) 0.58 × 0.39 × 0.21 
Data collection 
Diffractometer Bruker APEX-II CCD diffractometer 
Absorption correction Multi-scan 
SADABS Bruker 2014 
Tmin, Tmax 0.379, 0.664 
No. of measured, independent and 
observed [I> 2σ(I)] reflections 
3245, 3245, 2664 
Rint 0.0000 
R[F2> 2σ(F2)], wR(F2), S 0.047, 0.142, 1.05 
No. of reflections 3245 
No. of parameters 291 
No. of restraints 0 
H-atom treatment H atoms treated by a mixture of independent and constrained 
refinement 
Δρmax, Δρmin (e Å−3) 0.43, −0.43 
 
Table 2: Selected geometric parameters, bond lengths and bond angles (Å, °) 
 
Atoms bond lengths (Å) Atoms bond angles (°) 
Cl1—C16 1.736 (2) N1—O1—C13 113.28 (14) 
O1—N1 1.433 (2) O1—N1—C7 110.18 (15) 
O1—C13 1.354 (2) C9—N2—C10 126.8 (4) 
O2—C13 1.190 (3) C9—N2—C12 129.0 (6) 
N1—C7 1.262 (2) N1—C7—C6 115.83 (17) 
N2—C9 1.462 (5) N1—C7—C8 123.6 (2) 
N2—C10 1.365 (8) N2—C9—C8 111.3 (3) 
N2—C12 1.326 (12) N2—C10—C11 105.1 (7) 
N2A—C12A 1.36 (3) N3—C11—C10 110.7 (11) 
N2A—C9A 1.451 (15) N2—C12—N3 115.6 (10) 
N2A—C10A 1.31 (3) O1—C13—O2 124.75 (19) 
N3—C12 1.268 (15) O1—C13—C14 110.28 (15) 




Figure 1: ORTEP diagram of the titled compound 4 drawn at 50% ellipsoids for non-hydrogen atoms 
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Figure 2: Crystal packing showing intermolecular C—H•••O hydrogen bonds as dashed lines along the c axis. 




The target compound 4 displayed potential in 
vitro anti-Candida activity and it has been 
examined using clinical isolates of C. albicans 
and C. tropicalis. These clinical isolates were 
practically considered resistant to the gold 
standard antifungal drug, fluconazole (MIC ˃ 
1.6325 µmol/mL). The test compound 4 exhibited 
MIC values of 0.0221 and 0.7069 µmol/mL being 
about 74 and two folds more potent than 
fluconazole against C. albicans and C. tropicalis, 
respectively [8]. 
 
X-ray crystallography is a crucial analytical tool 
which can confirm the configuration of the titled 
oxime ester 4. Accordingly, the assigned (E)-
configuration of the titled compound 4 was 
established via its single crystal x-ray structure. 
The crystal structure of the titled compound 
contains one molecule in the asymmetric unit. 
The imidazole ring and ethyl side chain are 
statistically disordered over two conformations 
with a site-occupancy ratio of 0.785 (6): 0.215 
(5). Similarity, (SAME) restraint was used for the 
major and minor components of the disordered 
imidazole ring and ethyl side chain (C8-C9-N2-
C10-C11-N3-C12). The phenyl ring (C1-C6) 
forms dihedral angles of 1.54 (3)° with the major 
component of 3-chloro-benzene ring (C14-C19). 
The phenyl ring (C1-C6) also forms dihedral 
angles of 27.00° and 15.86(2)° with the major 
and minor components of the imidazole ring (N2-
C10-C11-N3-C13) respectively. The crystal 
structure is stabilized by C-H…O non-classical 
hydrogen bonds along the c axis, where the 
length between C2—H2A is 0.93 Å and between 
H2A•••O2 is 2.51 Å and the angle between C2—
H2A•••O2 is 138.00° with symmetry code: −x+1, 




Single-crystal x-ray structure of the anti-Candida 
agent, namely (E)-3-(1H-imidazol-1-yl)-1-
phenylpropan-1-one O-3-chlorobenzoyl oxime (4) 
is reported. The assigned (E)-configuration of the 
title compound 4 is confirmed via its doubtlessly 
single-crystal x-ray structure. The oxime ester 4 
could be considered as an imidazole-bearing 
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